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PL 31-343 Cracow, Poland; kurczab@if-pan.krakow.pl
* Correspondence: j.handzlik@uj.edu.pl; Tel.: +48-12-620-5580
Academic Editors: Pedro A. Sánchez-Murcia, Alba Gigante and Víctor Sebastián Pérez
Received: 21 October 2019; Accepted: 3 December 2019; Published: 6 December 2019


Abstract: Though the 5-HT6 serotonin receptor is an important target giving both agonists and
antagonists similar therapeutic potency in the treatment of topic CNS-diseases, no 5-HT6R ligand
has reached the pharmaceutical market yet due to the too narrow chemical space of the known
5-HT6R agents and insufficient “drugability.” Recently, a new group of non-indole and non-sulfone
hydantoin-triazine 5-HT6R ligands was found, where 3-((4-amino-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidazolidine-2,4-dione (KMP-10) was the
most active member. This study is focused on wider pharmacological and “druglikeness”
characteristics for KMP-10. A computer-aided insight into molecular interactions with 5-HT6R
has been performed. “Druglikeness” was examined using an eight-test panel in vitro, i.e., a parallel
artificial membrane permeability assay (PAMPA), and Caco-2 permeability-, P-glycoprotein (Pgp)
affinity-, plasma protein binding-, metabolic stability- and drug–drug interaction-assays, as well
as mutagenicity- and HepG2-hepatotoxicity risk tests. Behavioral studies in vivo, i.e., elevated
plus-maze (EPM) and novel object recognition (NOR) tests, were performed. Extended studies on
the influence of KMP-10 on rats’ metabolism, including biochemical tests, were conducted in vivo.
Results indicated significant anxiolytic and precognitive properties, as well as some anti-obesity
properties in vivo, and it was found to satisfy the “druglikeness” profile in vitro for KMP-10. The
compound seems to be a good lead-structure and candidate for wider pharmacological studies in
search for new CNS-drugs acting via 5-HT6R.
Keywords: 5-HT6R antagonist; 1,3,5-triazine; hydantoin; ADME-Tox parameters; procognitive
effect; obesity
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1. Introduction
Serotonin receptors 5-HT6 (5-HT6Rs) seem to be the most intriguing among the members of
5-HTRs family and also highly promising as a target for innovative therapy of CNS (central nervous
system)-diseases. Firstly cloned in rat in 1993 [1,2], and in a human in 1996 [3], they represent
the youngest 5-HTRs subtype with a unique distribution that is almost exclusively limited to brain
areas, especially those responsible for memory and cognitive processes, i.e., the dorsal hippocampus,
striatum and prefrontal cortex (PFC). In the PFC, which is critical to normal cognitive processes,
e.g., attention, impulsivity, planning, decision-making, working memory, and the learning or recall
of learned memories, the 5-HT6Rs occur in pyramidal cells and GABAergic (Gamma-AminoButyric
Acid) interneurons, where they regulate neurotransmitter systems that affect the aforementioned
processes [4,5]. Thus, the ligands of 5-HT6R seem to be pivotal for the successful treatment of
cognitive impairment. Predominantly, lines of evidence have indicated memory and learning ability
improvement effects, useful in mild and moderate form of Alzheimer’s disease (AD) and age-related
cognitive decline as well as antidepressant-like, anxiolytic-like, and anti-obesity properties for 5-HT6R
antagonists, while similar effects has also been confirmed for some 5-HT6R agonists [3,4,6–8]. This
paradox, although speaking in favor to 5-HT6R as a target, is still waiting to be explained. Several
hypotheses have postulated the following reasons: (i) the non-selective 5-HT6R action of reference
ligands used in pharmacologic assays, (ii) the regional and/or (iii) functional specificity of ligands. Each
of them is distinctly ligand’s structure-dependent. In this context, a search for new and structurally
different ligands for the 5-HT6 receptor is in a great scientific importance.
The results of studies in years 1995–2015 have provided more than 3000 active 5-HT6R ligands, but
their structural diversity is rather poor, including more than 80% of sulfone-containing structures and
more than 40% of indole-containing ones [9]. Among 17 antagonists that have reached clinical trials, only
one non-sulfonyl and non-indole structure (1, Figure 1) can be found [4,7,10]. The situation has not been
improved during last four years, providing new active compounds among 1H-pyrrolo[3,2-c]quinolones
(2) [11], N1-azinylsulfonyl-1H-indoles (3) [12], spiro[pyrrolidine-3,3′-oxindoles] (4) [13] and tricyclic
pyrano[2,3,4-cd]indoles (5) [14] (Figure 1), thus indicating a strong need to extend the chemical space
of 5-HT6R ligands.
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Figure 1. Predominant sulfone- and i le-containing st uctur s f serotonin receptors 5-HT6
(5-HT6R) ligands found previously: the only one non-sulfonyl and non-indole structure in clinical
trials (1) [4]; the most active 5-HT6R agents that represent the chemical families recently found in
primary screenings, i.e., 1H-pyrrolo[3,2-c]quinolones (2) [11], N1-azinylsulfonyl-1H-indoles (3) [12],
spiro[pyrrolidine-3,3′-oxi doles] (4) [13] and tricyclic pyrano[2,3,4-cd] ndoles (5) [14]; the most
advanced compounds in clinical trials towards Alzheimer’s disease (AD), i.e., Idalopirdine (6),
Intepirdine (7) and SUVN-502 (8) [15].
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Furthermore, the above 20-year intensive search for 5-HT6R agents has not provided any
compound that reached the pharmaceutical market. Among the most advanced ones investigated
in potential usage for AD treatment, Idalopirdine (6) and Intepirdine (7) failed phase III of clinical
trials, while SUVN-502 (8) gives a great hope because it has been successful in ongoing phase II trials
(Figure 1) [15]. An unsatisfactory “drugability,” the so called “ADMET (absorption, distribution,
metabolism, elimination, toxicity) profile,” of the earlier investigated 5-HT6R ligands was one of
the main reasons which disqualified them in the primary stages of drug R&D [16]. Thus, ADMET
screening, including an estimation of: (i) bioavailability, (ii) blood–brain penetration, (iii) clearance, and
(iv) the risk of toxic effects, is extremely desirable for the potent 5-HT6R agents identified in primary
pharmacological studies.
The briefly outlined “state of art” significantly underlines a great need to search for new chemical
families of 5-HT6R agents with a beneficial ADMET profile that would be useful either to give an
insight into the molecular level of the agonist–antagonist paradox or in order to find a new solution for
the therapy of current civilization diseases.
As a response to the aforementioned challenges, we discovered a new chemical class of non-indole
and non-sulfonyl 1,3,5-triazine derivatives that displayed a potent affinity and selectivity towards
5-HT6R in vitro together with antidepressant-like activity in primary screening in vivo [17–19]. Among
them, two series that contained the cyclic hydantoin spacer between aromatic moiety and the triazine
ring were explored (Figure 2).
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Figure 2. General structures of two series of 1,3,5-triazine hydantoin 5-HT6R agents found, Group
A and Group B, with respective “hits:” DJ-18 and 3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-
triazin-2-yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidazolidine-2,4-dione (KMP-10).
The series represent different substitution topologies, i.e., the 5,5-dimethyl-1-arylmethyl-hydantoin
derived compounds (Group A) and the 5-aryl-5-methyl-hydantoin derived ones (Group B, Figure 2).
Chemical modifications within both groups allowed us to identify two “hits,” DJ-18 and KMP-10,
where the last one was a distinctly more potent 5-HT6R agent (Figure 2; Table 1) that also showed
anxiolytic-like and antidepressant-like activity in vivo. Both compounds displayed anti-obsessive
properties in animals fed with the palatable feed and did not show cytotoxic effects on human
embryonic kidney (HEK)-293 cells in vitro [19].
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Table 1. Affinities for serotonin/dopamine receptors of hydantoin-triazine compounds DJ-18 and
KMP-10 [19].
Cpd Ki (nM)
a
5-HT6
[3H]-LSD
D2
[3H]-Raclopride
5-HT1A
[3H]-8-OH-DPAT
5-HT2A
[3H]-Ketanserin
5-HT7
[3H]-5-CT
DJ-18 127 4098 23,300 nt 3711
KMP-10 87 4247 14,160 17,170 514
Ref. [7] b [9] b [20] c - [18] d
a Tested experimentally in the radioligand binding assay, binding affinity, Ki, expressed as the average of at least two
independent experiments; nt—not tested. b–d Reference ligands for GPCRs investigated: b olanzapine, c buspirone,
d clozapine [19].
In this context, the present study was focused on the wider pharmacological and “druglikeness”
characteristics of KMP-10. An insight into molecular interactions of KMP-10 with a 5-HT6R receptor in
comparison to those of clinically advanced 5-HT6R ligands, Idalopirdine and SUVN-502 that belong to
different chemical groups, was performed in the first step. Then, “druglikeness” for the compound
was examined using a panel of eight ADMET tests in vitro. Behavioral studies in vivo to determine
anxiolytic-like and procognitive effects of KMP-10 were also performed. In the last step, extended
studies on the influence of the compound on body mass and rats’ metabolism, including biochemical
aspects, were carried out.
2. Results and Discussion
2.1. Molecular Modeling
Docking studies of KMP-10 in comparison to Idalopirdine (6) and SUVN-502 (8), representing two
different chemical groups of the most advanced 5-HT6R antagonists in clinical trials, were performed
(Figure 3).
Molecules 2019, 24, x 4 of 26 
Molecules 2019, 24, x; doi: www.mdpi.com/journal/molecules 
extended studies on the influence of the compound on body mass and rats’ metabolism, including 
biochemical aspects, were carried out. 
Table 1. Affinities for serotonin/dopamine receptors of hydantoin-triazine compounds DJ-18 and 
KMP-10 [19]. 
Cpd 
Ki (nM) a 
5-HT6 [3H]-
LSD 
D2 [3H]-
Raclopride 
5-HT1A [3H]-8-OH-
DPAT 
5-HT2A  
[3H]-Ketanserin 
5-HT7 [3H]-
5-CT 
DJ-18 127 4098 23,300 nt 3711 
KMP-10 87 4247 14,160 17,170 514 
Ref. [7] b [9] b [20] c - [18] d 
a Tested experimentally in the radioligand binding assay, binding affinity, Ki, expressed as the average 
of at least two independent experiments; nt—not tested. b−d Reference ligands for GPCRs investigated: 
b olanzapine, c buspirone, d clozapine [19]. 
2. Results and Discussion 
2.1. Molecular Modeling 
Docking studies of KMP-10 in comparison to Idalopirdine (6) and SUVN-502 (8), representing 
two different chemical groups of the most advanced 5-HT6R antagonists in clinical trials, were 
performed (Figure 3). 
 
Figure 3. Docking mode to 5-HT6R of Idalopirdine (A), SUVN-502 (B), and KMP-10 (C). 
In general, all docked compounds shared a common set of interactions with the 5-HT6 receptor, 
i.e., the salt bridge with D3.32 and CH- π with F6.52. Due to differences in the structure of these 
ligands (topologies), they showed different binding modes. Idalopirdine (Figure 3A, magenta) 
represented an extended conformation, where fluoroalkyl chain lied in proximity to asparagine N2.63 
(enabling the formation of a hydrogen-bond type of interaction) and aspartic acid D7.35 (in which it 
can form multipolar orthogonal type of interactions). SUVN-502 (Figure 3B, green) shows a 
representative binding mode of 5-HT6 antagonists [12,17,20], where the 2-Br substituted at the aryl 
ring was pointed (through the sp3 hybridization of sulfonamide linker) to a hydrophobic cavity 
formed by helixes 3–5. A slightly different way of interaction from Idalopiridine and SUVN-502 with 
the 5-HT6 receptor showed KMP-10 (Figure 3C, blue). The hydantoin ring formed an additional 
hydrogen bond with N6.55, which resulted in the anchoring of this fragment in place and the turning 
of the terminal naphthalene ring towards the extracellular part of the receptor. 
2.2. ADME-Tox Parameters In vitro 
2.2.1. Permeability Assays 
Parallel Artificial Membrane Permeability Assay (PAMPA) 
Figure 3. Docking mode to 5-HT6R of Idalopirdine (A), SUVN-502 (B), and KMP-10 (C).
In general, all docked compounds shared a common set of interactions with the 5-HT6 receptor,
i.e., the salt bridge with D3.32 and CH- π with F6.52. Due to differences in the structure of these ligands
(topologies), they showed different binding modes. Idalopirdine (Figure 3A, magenta) represented an
extended conformation, where fluoroalkyl chain lied in proximity to asparagine N2.63 (enabling the
formation of a hydrogen-bond type of interaction) and aspartic acid D7.35 (in which it can form
multipolar orthogonal type of interactions). SUVN-502 (Figure 3B, green) shows a representative
binding mode of 5-HT6 antagonists [12,17,20], where the 2-Br substituted at the aryl ring was pointed
(through the sp3 hybridization of sulfonamide linker) to a hydrophobic cavity formed by helixes 3–5. A
slightly different way of interaction from Idalopiridine and SUVN-502 with the 5-HT6 receptor showed
KMP-10 (Figure 3C, blue). The hydantoin ring formed an additional hydrogen bond with N6.55, which
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resulted in the anchoring of this fragment in place and the turning of the terminal naphthalene ring
towards the extracellular part of the receptor.
2.2. ADME-Tox Parameters In vitro
2.2.1. Permeability Assays
Parallel Artificial Membrane Permeability Assay (PAMPA)
One of the most commonly used screening methods of compound permeability is the testing of
their passive penetration through the bilayer artificial membranes. One of these methods, the pre-coated
parallel artificial membrane permeability assay (PAMPA) Plate System GentestTM (Corning, Tewksbury,
MA, USA) [21] was used during this study. This membrane consists of special structure of the lipids
and oil that may imitate barriers for compound absorption from the intestines with a good correlation
to in vivo conditions. Both tested ligands showed a higher permeability coefficient (Pe) than the
recommended by the PAMPA Plate System manufacturer value for permeable compounds, which was
1.5 × 10−6 cm/s [21], which was much higher than Pe estimated during this study for low-permeable
reference norfloxacin (Table 2). However, the obtained values differed between the tested 5-HT6
ligands. Compound DJ-18, with its p-chlorobenzyl substituent, had an excellent, ~1.65 stronger ability
to penetrate the artificial membrane than high-permeable reference caffeine, whereas KMP-10, with
a naphthyl substituent, showed a ~4-fold weaker permeability than caffeine (Table 2). The result
for DJ-18 confirmed our previous data, where the triazine-based 5-HT6R ligand with the presence
of chlorobenzyl moiety (Compound 1 in the reference [22]) was also shown as highly permeable
compound in PAMPA (Pe = 23.6 × 10−6 cm/s).
Table 2. Absorption, plasma protein binding (PPB) and pharmacokinetic properties determined in vitro.
Compound PAMPA Pe * [10
−6
cm/s] ± SD
Caco-2 Papp **
[10−6 cm/s] ± SD
PPB KD ***
[µM]
PPB fb ***
[%] ± SD
Half-Life t1/2 ****
[min]
Intrinsic Clearance
CLint ****
[mL min−1 kg−1]
DJ-18 24.9 ± 0.45 NT NT NT 187.29 4.32
KMP-10 3.76 ± 0.76 6.27 ± 0.30 112 84.5 ± 6.04 238.96 3.74
References
Caffeine 15.1 ± 0.40
Norfloxacin
0.56 ± 0.13
Caffeine
22.04 ± 0.38
Warfarin
9.50
Warfarin
98.5 ± 2.10 Verapamil 30.39 Verapamil 26.76
NT—not tested, * tested in triplicate, ** data from two experiments, *** calculated according to manufacturer
recommendations from eight wells—two references and six wells with increasing immobilized biological phases;
**** result based on four independent reactions terminated at different time points.
Permeability Assay with Using Caco-2 Cells
The absorption of compound KMP-10 was also tested in the cell-based Caco-2 assay, which allows
for the estimation of permeability in both the passive and active ways. The calculated for KMP-10
permeability coefficient (Papp) was 6.27 × 10−6 cm/s (Table 2). That result indicates KMP-10’s moderate
permeability according to proposed in the literature classification bands for the Caco-2 permeability
model [23], where Papp < 2 × 10−6 cm/s means a low permeability, a Papp value from 2 × 10−6 to
20 × 10−6 cm/s means moderate permeability, and a Papp value above 20 × 10−6 cm/s means a highly
permeable compound. In the present assay, caffeine was also used as good permeable compound with
its calculated Papp = 22.04 × 10−6 cm/s. Interestingly, KMP-10 had 4-fold weaker passive penetration
than caffeine in PAMPA, whereas it a showed slightly better result in the Caco-2 passive/active transport
model, where its absorption was only 3-fold weaker than caffeine (Table 2). Since the literature sources
indicated passive transport of caffeine through biological membranes [24], the estimated better result of
KMP-10 absorption in the Caco-2 model may be due to some up-take transporters, which are involved
in KMP-10 transport through the Caco-2 cells.
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Results of both the PAMPA and Caco-2 assays are in good concordance with previously performed
blood–brain barrier permeability simulation using QikProp from Schrödinger Suite software. The
in silico prediction also showed a moderate permeability properties for KMP-10, with a QPlogBB
parameter of −0.92 that was placed almost exactly in the middle of the range predicted for permeable
compounds (−0.3–1.2) [18].
2.2.2. Affinity to P-Glycoprotein
One of the most significant modification strategies for brain penetration improvement is reducing
P-glycoprotein (Pgp) efflux. Pgp is active efflux transporter in the lipid bilayer cell membranes of
the blood–brain barrier and the intestine. In addition to its influence on drugs’ brain penetration
abilities, this integral membrane protein also plays many roles in adverse drug–drug interactions (DDIs)
and multidrug resistance. Thus, it is very important to determine as early as possible, if potential
drug candidate stimulates or inhibits Pgp. The stimulation of ATP consuming by Pgp is caused
by compounds which are substrates for Pgp and may be measured luminescently by Pgp-ATPase
(AdenosineTriPhosphatase) assay test. In this assay, the influence of 5-HT6 ligands on Pgp basal
activity was estimated. The basal activity of Pgp was considered as the difference in the luminescent
signal between samples treated with 100 µM of the potent and selective Pgp inhibitor (Na3VO4) and
untreated samples (Figure 4). The stimulation effect was shown for the reference drug verapamil with
an increase in ATP consuming up to 175% of Pgp basal activity in a concentration of 200 µM. The
results obtained for 5-HT6R ligands indicated that none of the tested compounds was the substrate of
Pgp because they did not increase the Pgp activity at the tested concentration 100 µM, nor did they did
cause any statistically significant changes of basal Pgp activity. No strong substrate of Pgp among
triazine-derived 5-HT6R ligands had been found in our previous studies as well [22].
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2.2.3. Plasma Protein Binding
Binding to the plasma proteins should be investigated in the early stages of the drug discovery
process, as this pharmacological effect is exerted o ly by th unbound fraction (fu) of the drug, which
can penetr te the cell embranes. Many drugs, especiall lipophilic compounds, bind to ci culating
plasma proteins, su h as human serum albumin (HSA), α1-acid glycoprotein (AGP), globulins, and
li oproteins [25], e peci lly the HSA and AGP are proteins, which are mostly responsible for the
reduction of exposure to drugs. The immobilized HSA and AGP used in this study was included in
the commercial test TRANSILXL PPB (plasma protein bindi g) assay. The assay mimicked the plasma
physiological conditions, where HSA and AGP existed at the r tio of 24:1. Warfarin was us d a
positive control that was highly bound to plasma pro ins. The effect of this study ~98,5% fraction
of warfarin bound to plasma proteins (fb) was estimated and found to be similar to the results fr m
the lite ature [25,26]. In consequence, only 1.5% of the warfarin in the blood stream provided i s
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therapeutic effect. The tested triazine derivative KMP-10 showed a much better result than warfarin,
as its fb was calculated at 84.5% (Table 2). Moreover, the calculated equilibrium dissociation constant
(KD) for KMP-10 was ~10-fold higher than that for warfarin (112 vs. 9.50 µM, respectively; Table 2).
2.2.4. Metabolic Stability
The most probable structures of metabolites were determined in vitro by HLMs (human liver
microsomes) with support of the MetaSite 6.01 software (Figure 5). In silico predictions indicated the
same most probable site of metabolism for both compounds, which was N-methylpiperazine moiety
(Figure 5). Incubation with HLMs for 120 min resulted in the formation of four metabolites by each
compound (Table 3; Figure 6a,b). Moreover, the similar main metabolic pathway-demethylation at
the N-methylpiperazine moiety (the M1 metabolite) was determined for both the 5-HT6R ligands by
MS and MS/MS analyses (Table 3; Figures S1–S4 in Supplementary Information). That reaction was
also predicted by MetaSite with the highest, 100% probability (data not shown) and was observed in
our previous investigations on the metabolism of 1,3,5-triazine-methylpiperazine derivatives [22,27].
Other metabolic pathways included hydroxylations (both compounds) and dehydrogenation (KMP-10).
The presence of the metabolites that were obtained as the effect of further hydroxylation of the main
metabolites was also found (the M3 metabolite of DJ-18 and KMP-10; Table 3).
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Table 3. The metabolic pathways of DJ-18 and KMP-10.
Substrate MolecularMass (m/z)
Retention Time
(min)
Molecular Mass of
the Metabolite (m/z) Metabolic Pathway
DJ-18 459.3
3.99 M1 445.34 demethylation
4.21 M2 475.38 hydroxylation
4.42 M3 461.36 demethylation and hydroxylation
3.40 M4 475.38 hydroxylation
KMP-10 447.27
3.45 M1 433.25 demethylation
3.65 M2 463.22 hydroxylation
3.82 M3 449.26 demethylation and hydroxylation
4.26 M4 461.23 hydroxylation and dehydrogenation
Apart from the number of metabolites found, the predominant amount of untransformed
substrates, either KMP-10 or DJ-18, was confirmed by the analyses, which were able to prove the
good metabolic stability of both compounds. The pharmacokinetic properties of DJ-18 and KMP-10
were also determined in vitro using HLMs. Indeed, during the assay, both compounds were found
to be metabolically stable and showed similar, low intrinsic clearance CLint values th t were below
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the value estimated for low clearance compounds CLint = 8.6 mL min−1 kg−1 [28] (Table 2). Both
compounds also showed a long biological half-life (t1/2) that was ~6-fold (DJ-18) and ~8-fold (KMP-10)
longer than the reference—the unstable drug verapamil (Table 2). The observed good pharmacokinetic
properties correspond with results of the previously tested 5-HT6R triazine ligands (with a CLint value
also below 8.6 mL min−1 kg−1) [22]. In this context, the properties of KMP-10 were even better than
those of the most active 5-HT6R agent found earlier, the thymol-1,3,5-triazine derivative MST4 (4 in the
reference [22]), and in the range of the indolemethyl triazine derivative (3 in the reference [22]).
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2.2.5. Drug–Drug Interactions (DDIs)
The influence of triazine derivatives on two the most involved in drug metabolism CYP (cytochrome
P450) isoforms CYP3A4 and CYP2D6 was also investigated. DJ-18 showed inhibition effects up to
~42% of CYP3A4 activity, but only at the highest concentrations ≥ 10 µM. On the other hand, a slight
stimulation effect of CYP3A4 was observed for KMP-10 at the highest used dose of 25 µM (Figure 7a).
Both compounds also slightly induced CYP2D6 (Figure 7b). In summary, the compounds showed
very low or no risk of DDIs in comparison to the reference inhibitors quinidine and ketoconazole,
a results that correlates with previous data obtained for another 5-HT6R ligands from the group of
1,3,5-triazine-methylpiperazines [22].
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 Figure 7. Effect of reference inhibitor (ketoconazole), KMP-10 and DJ-18 on CYP3A4 activity (a). Effect
of reference inhibitor quinidine, KMP-10 and DJ-18 on CYP2D6 activity (b). The compounds were
examined in triplicate.
2.2.6. Ames Test
The Ames test received the requirements of OECD (Organisation for Economic Co-operation
and Development) and is the “gold standard” for testing of chemicals mutagenicity. The Salmonella
typhimurium TA100 strain is used in Ames test for detection of mutagens that cause base-pair substitution
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mutations primarily at one of the GC pairs, which reverted TA100 to the wild-type state. During
this study, the medium control baseline (MCB) was calculated first, which is an average of mean
revertants (positive wells) from vehicle control (1% DMSO in growth media) plus one standard
deviation (SD). Next, it was investigated if the tested compounds were able to cross of the threshold
of 2 ×MCB, which is considered the mutagen alert. As shown in Figure 8, similarly to our previous
results for another triazine-based 5-HT6R ligands [22], none of the tested compounds presented any
mutagenic effects. The only one which crossed the mutagen alert line was the reference compound
nonyl-4-hydroxyquinoline-N-oxide (NQNO) at a concentration 0.5 µM. For this reference, 46 positive
wells were measured with fold increase over MCB = 5.41 (Figure 8).
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The cell-based assays were used to investigate safety of the 5-HT6R ligands. In our previous 
studies [19], the statistically significant slight decrease of HEK-293 cells viability was estimated for 
DJ-18 at the highest concentration 100 μM. During the same study, no effect for KMP-10 was observed 
[19]. Additional safety tests with the hepatoma HepG2 cell line were performed here to estimate the 
compounds’ hepatotoxicity. A slight antiproliferative effect was observed only for DJ-18 at 100 μM, 
where the cell viability was decreased to up to ~83% of the control (Figure 9a). KMP-10 did not show 
any hepatotoxic character (Figure 9b). In general, taking into account the results of our present and 
previous safety assays, all of the to date tested 1,3,5-triazine-methylpiperazines from our compound 
library showed weak or no cytotoxic activity [19,22]. 
Figure 8. The number of revertants of the Salmonella typhimurium TA100 strain exposed to the
reference mutagen nonyl-4-hydroxyquinoline-N-oxide (NQNO, 0.5 µM) and 5-HT6R ligands in two
concentrations of 1 and 10 µM. The dashed line marks the doubled medium control baseline (MCB).
The c mpounds were examined in triplicate.
2.2.7. Hepatotoxicity Assay
The cell-based assays were used to investigate safety of the 5-HT6R ligands. In our previous
studies [19], th statistic lly significant slight decreas of HEK-293 cells viability was estimat d for DJ-18
at the highest concentration 100 µM. During the same study, no effect for KMP-10 was observed [19].
Additional safety tests with the hepatoma HepG2 cell line were performed here to estimate the
compounds’ hepatotoxicity. A slight antiproliferative effect was observed only for DJ-18 at 100 µM,
where the cell viability was decreased to up to ~83% of the control (Figure 9a). KMP-10 did not show
any hepatotoxic character (Figure 9b). In general, taking into account the results of our present and
previous safety assays, all of the to date tested 1,3,5-triazine-methylpiperazines from our compound
library showed weak or no cytot xic activity [ , ].
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CLint (53 mL/min/kg). The corresponding parameters tested in vitro for KMP-10 were even better (>3 
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Figure 9. The effect of reference cytostatic drug doxorubicin (DX, 1 µM), DJ-18 (a) and KMP-10 (b) on
the viability of HepG2 cell line. DMSO 1% in cell growth media (vehicle) was used as a control.
Statistical significance (*** p < 0.001, * p < 0.05) was analyzed by Graph Pad PrismTM 6 software using a
one-way ANOVA and Bonferroni’s multiple comparison post-hoc test. The compounds were examined
in quadruplicate.
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2.2.8. “Druglikeness” of KMP-10 in Comparison to SUVN-502
In 2017, Nirogi et al. [29] described “druglikeness” profile for SUVN-502 based on both
in vitro and in vivo assays. Though the assays were not identical to those we used in our assays
presented for KMP-10, they gave some trends of results that can be comparable. Hence, the
aforementioned results indicated that SUVN502 is rather strong inhibitor of CYP3A4 and a weaker
inhibitor of CYP2D6, while KMP-10 had almost no influence any of the tested CYP isoforms. The
pharmacokinetics investigated in vivo for SUVN-502 indicated beneficial values of t1/2 (0.95 h) and
CLint (53 mL/min/kg). The corresponding parameters tested in vitro for KMP-10 were even better
(>3 h and 3.74 mL/min/kg, respectively; Table 2). The results of Nirogi et al. demonstrated good BBB
(blood brain barrier)-penetration for SUVN-502 after oral administration. Though we did not have the
ability to perform the same assays for KMP-10, our in vitro PAMPA and Caco-2 permeability results
and suggest an optimistic prognosis for similar behavior in vivo of this hydantoin-triazine derivative.
In this context, KMP-10 seems to be promising candidate for further drug R&D.
2.3. Behavioral Test In vivo
2.3.1. Anxiolytic-Like Activity of Compound KMP-10
In our previous work [19], the anxiolytic-like effects of KMP-10 were confirmed in a Vogel-conflict
test that is the “conditional” anxiety-like assays. This study investigated the anxiolytic-like action in
the elevated plus-maze (EPM) test, an “unconditional” assay based on rodents’ natural aversion to
heights and open space (Figure 10).Molecules 2019, 24, x 11 of 26 
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Figure 10. Anxiolytic-like effects of KMP-10 in the elevated plus-maze (EPM) test. Increased open-
arm exploration denotes reduced anxiety. KMP-10 was intraperitoneally (i.p.) injected 60 min before 
the test. Values represent the mean ± SEM of the time (a) and percentage of time (b) spent in open 
arms, entries (c) and percentage of entries (d) distance traveled in the open arms during the five-
minute test session (e) compared to the respective vehicle group. * p < 0.05, ** p < 0.01, ***p < 0.001 
(ANOVA was followed by the Bonferroni’s post-hoc test), and N = 7–8. 
Compound KMP-10 showed anxiolytic-like activity at the doses of 1 and 3 mg/kg. In this test, 
KMP-10 increased the time spent in the open arms (ANOVA F(3,22) = 17.100; p < 0.0001), the 
percentage of time spent in the open arms (ANOVA F(3,22) = 15.774; p < 0.0001) and the distance 
travelled in the open arms (ANOVA F(3,22) = 5,7922; p < 0.01). The observed anxiolytic-like activity 
of compound KMP-10 was specific, and no changes in locomotor activity were observed in EPM test 
(data not shown). 
2.3.2. Novel Object Recognition (NOR) Test 
KMP-10 at the full dose-range (0.3–3 mg/kg) significantly and dose-dependently reversed the 
memory deficits induced by scopolamine in the novel object recognition (NOR) test, while during the 
memory impairment induced by MK-801, some activity at the dose of 1 mg/kg of KMP-10 was 
observed, but the discrimination index did not reach a statistically significant level (Figure 11). 
Figure 10. Anxiolytic-like effects o KMP-10 in the el vated plus- (EPM) test. Increased open-arm
exploration denotes reduced anxiety. KMP-10 was intraperitoneally (i. .) injected 60 min before the
test. Values represent the mean ± SEM of the time (a) and percentage of time (b) spent in open arms,
entries (c) and percentage of entries (d) distance traveled in the open arms during the five-minute test
session (e) compared to the respective vehicle group. * p < 0.05, ** p < 0.01, ***p < 0.001 (ANOVA was
followed by the Bonferroni’s post-hoc test), and N = 7–8.
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Compound KMP-10 showed anxiolytic-like activity at the doses of 1 and 3 mg/kg. In this
test, KMP-10 increased the time spent in the open arms (ANOVA F(3,22) = 17.100; p < 0.0001), the
percentage of time spent in the open arms (ANOVA F(3,22) = 15.774; p < 0.0001) and the distance
travelled in the open arms (ANOVA F(3,22) = 5,7922; p < 0.01). The observed anxiolytic-like activity of
compound KMP-10 was specific, and no changes in locomotor activity were observed in EPM test
(data not shown).
2.3.2. Novel Object Recognition (NOR) Test
KMP-10 at the full dose-range (0.3–3 mg/kg) significantly and dose-dependently reversed the
memory deficits induced by scopolamine in the novel object recognition (NOR) test, while during
the memory impairment induced by MK-801, some activity at the dose of 1 mg/kg of KMP-10 was
observed, but the discrimination index did not reach a statistically significant level (Figure 11).
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Figure 11. Effect of compound KMP-10 on the memory impairment induced by scopolamine (a) and 
MK-801 (b) in the novel object recognition (NOR) test. Compound KMP-10 was i.p. administered 60 
min, while scopolamine s.c. and MK were i.p. administered 30 min before the T1 session. The animals 
were observed for five min. The data are presented as the mean ± SEM of six-to-eight rats. The data 
were statistically evaluated by a one-way ANOVA followed by Bonferroni’s post-hoc test, * p < 0.05, 
and *** p < 0.001 vs respective vehicle group, and # p < 0.05, ## p < 0.01 and #### p < 0.0001 vs respective 
scopolamine treated group. For the one-way ANOVA for compound KMP-10 for scopolamine-
induced memory impairment, F(4,31) = 10.640; p < 0.0001, and, for the MK-801-induced memory 
impairment, F(4,29) = 1.000; NS (not significant). 
2.4. Metabolic Test In vivo 
In order to extend the previously investigated [19] basic influence of KMP-10 on food-induced 
the body-mass increase, this study was focused on deeper insight into the action, i.e.,: (i) the influence 
on caloric and water intakes of either obese or standard fed rats, (ii) the influence of the three-week 
chronic treatment with KMP-10 on the amount of peritoneal adipose tissue and liver mass, (iii) the 
influence of KMP-10 on blood glucose, cholesterol and triglyceride levels in the model of excessive 
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2.4.1. Influence of KMP-10 on Caloric and Water Intakes of Obese Rats 
In the tested group, KMP-10 intraperitoneally (i.p.) administered significantly reduced the 
amount of calories consumed by the animals (starting from the first week of the experiment), but not 
water intake, in comparison to the obesity control group (Figures 12a,b and 13a,b). 
Figure 11. Effect of compound KMP-10 on the memory impairment induced by scopolamine (a) and
MK-801 (b) in the novel object recognition (NOR) test. Compound KMP-10 was i.p. administered
60 min, while scopolamine s.c. and MK were i.p. administered 30 min before the T1 session. The
animals were observed for five min. The data are presented as the mean ± SEM of six-to-eight rats.
The data were statistically evaluated by a one-way ANOVA followed by Bonferroni’s post-hoc test,
* p < 0.05, and *** p < 0.001 vs. respective vehicle group, and # p < 0.05, ## p < 0.01 and #### p < 0.0001
vs. respective scopolamine treated group. For the one-way ANOVA for compound KMP-10 for
scopolamine-induced memory impairment, F(4,31) = 10.640; p < 0.0001, and, for the MK-801-induced
memory impairment, F(4,29) = 1.000; NS (not significant).
2.4. Metabolic Test In vivo
In order to extend the previously investigated [19] basic influence of KMP-10 on food-induced the
body-mass increase, this study was focused on deeper insight into the action, i.e.,: (i) the influence
on caloric and water intak s of either obes or standard fed rats, (ii) the influence of the three-we k
c ronic treatme t with KMP-10 on the amount of p ritoneal adipose tissue a d liver mass, (iii) th
influence of KMP-10 o blood glucose, cholesterol and triglyceride lev ls in the m del of excessive
eating, and (iv) the influence of KMP-10 on a spontaneous activity test.
2.4.1. Influence of KMP-10 on Caloric and Water Intakes of Obese Rats
In the tested group, KMP-10 intraperitoneally (i.p.) administered significantly reduced the amount
of calories consumed by the animals (starting from the first week of the experiment), but not water
intake, in comparison to the obesity control gr up (Figures 12a,b and 13a,b).
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Figure 12. Effect of long-term administration of KMP-10 on food intake in male Wistar rats (a). Food 
intake by male Wistar rats fed with palatable diet in particular weeks (b). Sum of food intake by male 
Wistar rats fed with palatable diet (c). Food intake by male Wistar rats fed with standard diet in 
particular weeks (d). Sum food intake by male Wistar rats fed with standard diet. Results are mean 
data for two animals housed together, n = 8. ^ Comparisons vs. the vehicle-treated control group fed 
palatable diet; * comparisons versus the vehicle-treated control group fed standard diet, the two-way 
ANOVA (a,c) and the Student’s t-test (b,d); ^^, ** p < 0.01; and ^^^, *** p < 0.001. 
2.4.2. Effect of KMP-10 on Calorie and Water Intakes in Rats Fed Standard Diet 
Starting from the first week of the experiment, KMP-10 i.p. administered at a dose of 5 mg/kg 
b.w. significantly reduced the amount of calories consumed by the animals in the test group as 
compared with the control group. Results are shown in Figure 12c,d. A significantly lower water 
intake in the tested groups as compared to the control group was also observed (Figure 13c,d). 
Figure 12. Effect of long-term administration of K -10 on food i tak in m le Wistar rats (a). Food
intake by male Wistar rats fed with palatable diet in particular weeks (b). Sum of food intake by
male Wistar rats fed with palatable diet (c). Food intake by male Wistar rats fed with standard diet in
particular weeks (d). Sum food intake by male Wist r rats fed with st ndard diet. Results are mean
data for two animals housed together, n = 8. ˆ Comparisons vs. the vehicle-treated control group fed
palatable diet; * comparisons versus the vehicle-treated control group fed standard diet, the two-way
ANOVA (a,c) and the Student’s t-test (b,d); ˆˆ, ** p < 0.01; and ˆˆˆ, *** p < 0.001.
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Figure 13. Effect of long-term administration of KMP-10 on water intake in male Wistar rats (a). Water 
intake by male Wistar rats fed with palatable diet in particular weeks (b). Sum of water intake by male 
Wistar rats fed with palatable diet (c). Water intake by male Wistar rats fed with standard diet in 
particular weeks (d). Sum of water intake by male Wistar rats fed with standard diet. Results are mean 
data for two animals housed together, n = 8. * Comparisons versus the vehicle-treated control group 
fed standard diet, a two-way ANOVA (a,c) and the Student’s t-test (b,d); * p < 0.05 and ** p < 0.01. 
2.4.3. Influence on the Amount of Peritoneal Adipose Tissue and Liver Mass 
The influence of the three-week chronic treatment with KMP-10 on the amount of peritoneal 
adipose tissue and liver mass is shown in Figure 14. 
Figure 13. Effect of long-term administration of K -10 on wa er take in m le Wis ar rats (a). Water
intake by male Wistar rats fed with palatable diet in particular weeks (b). Sum of water intake by
male Wistar rats fed with palatable diet (c). Water intake by male Wistar rats fed with standard diet in
particular weeks (d). Sum of water intake by male Wistar rats fed with standard diet. Results are mean
data for two animals housed together, n = 8. * Comparisons versus the vehicle-treated control group
fed standard diet, a two-way NOVA (a,c) and the Student’s t-test (b,d); * p < 0.05 and ** p < 0.01.
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2.4.2. Effect of KMP-10 on Calorie and Water Intakes in Rats Fed Standard Diet
Starting from the first week of the experiment, KMP-10 i.p. administered at a dose of 5 mg/kg b.w.
significantly reduced the amount of calories consumed by the animals in the test group as compared
with the control group. Results are shown in Figure 12c,d. A significantly lower water intake in the
tested groups as compared to the control group was also observed (Figure 13c,d).
2.4.3. Influence on the Amount of Peritoneal Adipose Tissue and Liver Mass
The influence of the three-week chronic treatment with KMP-10 on the amount of peritoneal
adipose tissue and liver mass is shown in Figure 14.Molecules 2019, 24, x 15 of 26 
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Figure 14. Effects of long-term administration of KMP-10 on amount of peritoneal fat (a,b) and liver 
weight (c,d) in male Wistar rats. Results are means ± SEM, n = 8. Comparisons were performed by a 
Student’s t-test.  
Animals consuming the palatable feed had a significant increase of fat in peritonea vs animals 
consuming the standard feed. The fat pads in the animals from the control group fed the palatable 
feed weighed, on average, about 5.42 g more than in animals from the control group fed the standard 
feed (increase by 91.5%) (*** p < 0.001; Student’s t-test). The group that received the tested compound 
had a comparable amount of fat in the peritonea, as compared to the control rats (Figure 14a,b). Liver 
in the animals from control group fed the palatable feed weighed, on average, about 3.38 g more than 
in animals from the control group fed the standard feed (increase by 37.3%) (*** p < 0.001; Student’s 
t-test). The livers in the tested groups had about the same mass as the livers in the control groups 
(Figure 14c,d). 
2.4.4. Influence of Diet or of KMP-10 on Blood Glucose, Cholesterol and Triglyceride Levels in the 
Model of Excessive Eating 
In animals fed with the palatable feed, the blood glucose level and blood triglyceride level were 
significantly higher than those in the control group fed the standard feed; results are shown in Figure 
15a,b. KMP-10, at a dose of 5 mg/kg b.w., significantly decreased the total cholesterol in blood in 
comparison to the group fed the palatable feed (Figure 15c) and significantly increased HDL (high 
density lipoprotein) cholesterol (Figure 15d). 
Figure 14. Effects of long-term administration of KMP-10 on amount of peritoneal fat (a,b) and liver
weight (c,d) in male Wistar rats. Results are means ± SEM, n = 8. Comparisons were performed by a
Student’s t-test.
Animals consuming the palatable feed had a significant increase of fat in peritonea vs. animals
consuming the standard feed. The fat pads in the animals from the control group fed the palatable
feed weighed, on average, about 5.42 g more than in animals from the control group fed the standard
feed (increase by 91.5%) (*** p < 0.001; Student’s t-test). The group that received the tested compound
had a comparable amount of fat in the peritonea, as compared to the control rats (Figure 14a,b). Liver
in the animals from control group fed the palatable feed weighed, on average, about 3.38 g more than
in animals from the control group fed the standard feed (increase by 37.3%) (*** p < 0.001; Student’s
t-test). The livers in the tested groups had about the same mass as the livers in the control groups
(Figure 14c,d).
2.4.4. Influence of Diet or of KMP-10 on Blood Glucose, Cholesterol and Triglyceride Levels in the
Model of Excessive Eating
In animals fed with the palatable feed, the blood glucose level and blood triglyceride level
were sig ificantly higher than those in the contr l gro p fed th standard feed; results are shown
in Figure 15a,b. KMP-10, at a dose of 5 mg/kg b.w., significantly decreas d the total cholesterol in
blood in comparison t the group fed the palatable feed (Figure 15c) and significantly increased HDL
(high density lipoprotein) cholesterol (Figure 15d).
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Figure 15. Effects of diet or of long-term administration of KMP-10 on blood glucose level (a), blood 
triglyceride level (b), blood total cholesterol level (c), or blood HDL (High-density lipoprotein) 
cholesterol level (d) in male Wistar rats in the excessive eating model. Results are means ± SEM, n = 
8. Concentrations in blood: mg/dl. Comparisons versus the vehicle-treated control group (*) or versus 
the vehicle-treated excessive eating control groups (^) were performed by the Student’s t-test, 
significant differences are denoted by *, ^ p < 0.05, ** p < 0.01, ^^^ p < 0.001. 
2.4.5. The Influence of KMP-10 on Spontaneous Activity Test 
In the group treated with the tested compound and fed the palatable feed, no statistically 
significant effect on the spontaneous activity was observed in comparison with the control group fed 
the palatable feed on day 1, 14 or 20 (Figure 16). 
Figure 15. Effects of diet or of long-term administration of KMP-10 on blood glucose level (a),
blood triglyceride level (b), blood total cholesterol level (c), or blood HDL (High-density lipoprotein)
cholesterol level (d) in male Wistar rats in the excessive eating model. Results are means ± SEM, n = 8.
Concentrations in blood: mg/dl. Comparisons versus the vehicle-treated control group (*) or versus the
vehicle-treated excessive eating control groups (ˆ) were performed by the Student’s t-test, significant
differences are denoted by *, ˆ p < 0.05, ** p < 0.01, ˆˆˆ p < 0.001.
2.4.5. The Influence of KMP-10 on Spontaneous Activity Test
In the group treated with the tested compound and fed the palatable feed, no statistically significant
effect on the spontaneous activity was observed in comparison with the control group fed the palatable
feed on day 1, 14 or 20 (Figure 16).
2.4.6. Discussion on the Influence of KMP-10 on Metabolism
The 5-HT6 receptor blockade has been implicated in the reduction of food intake, body weight,
visceral adiposity, and insulin resistance [30]. 5-HT6 receptor antagonists block the serotonin-dependent
activation of γ-aminobutyric acid (GABA) neurons, which results in a reduction of inhibitory effects
of GABA on proopiomelanocortin neurons in the arcuate nucleus, with the subsequent inhibition of
hunger signal induction [31]. Our previous results indicated that an administration of KMP-10 to
rats in the overeating model caused a significantly lower increase of body mass when compared to
that of the control group [19]. The results of the present study suggest a reduced calorie intake by
rats as a probable reason. Food consumption in rats and mice can be decreased not only through the
enhancement of satiety but also because of various factors including stress, sickness, sedation and
drug-induced toxicity [32]. In our studies, the effect of compound KMP-10 on spontaneous activity
was not observed. Hence, it is certain that the weight reduction and calorie intake were not associated
with sedation. In order to exclude other reasons for the lower food intake and body mass increase,
further studies are required. Nevertheless, it is worth underlining that the confirmed significant action
of KMP-10 on 5-HT6R can be a basis for the inhibition of hunger signal induction caused by this
compound. This is consistent to the previous lines of evidence that indicated an anorexic effect of other
5-HT6R ligands, and effect which was associated with a reduced food intake via the mechanism related
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to the enhancement of satiety [30]. Furthermore, comparable results in terms of parameters, such as
body weight and the amount of calories consumed, have been provided by earlier studies for another
5-HT6R ligand, Idalopirdine [33]. In contrast to KMP-10, Idalopirdine also compensated for elevated
glucose levels and significantly reduced the amount of visceral fat. KMP-10 did not reduce the amount
of either peritoneal fat or plasma triglyceride and glucose. However, it should be emphasized that the
administration of KMP-10 caused a significant increase in the level of HDL-cholesterol in the plasma.
Thus, the correction of metabolic changes certainly started in the right direction.Molecules 2019, 24, x 17 of 26 
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Figure 16. Changes in the spontaneous activity after single (a) and fourteen (b) and twenty (c) day 
administration of KMP-10 to rats fed palatable diet. Results are mean ± SEM; n = 8, comparisons versus 
the vehicle-treated excessive eating control groups (two-way ANOVA). 
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Figure 16. Changes in the spontaneous activity after single (a) and fourteen (b) and twenty (c) day
administration of KMP-10 to rats fed palatable diet. Results are mean ± SEM; n = 8, comparisons versus
the vehicle-treated excessive eating control groups (two-way ANOVA).
3. Materials and Methods
3.1. Molecular Modeling
The procedure of 5-HT6R homology model generation was based on the β2 adrenergic receptor
template, and docking studies were performed according to our methods described earlier [17–19].
3.2. ADME-Tox Parameters In vitro
3.2.1. References
The compounds used as the references—caffeine (CFN), doxorubicin (DX), ketoconazole (KE),
nonyl-4-hydroxyquinoline-N-oxide (NQNO), norfloxacin (NFX), sulfaphenazole (SE), quinidine (QD)
and warfarin (WFN)—were obtained from Sigma-Aldrich (St. Louis, MO, USA). The references for
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Pgp activity and pharmacokinetic studies—verapamil (VL) and Na3VO4—were provided with the
luminescent Pgp-GloTM Assay System (Promega, Madison, WI, USA).
3.2.2. Permeability Assay
The PAMPA Plate System GentestTM was purchased from Corning (Tewksbury, MA, USA).
The 10 mM stocks (DMSO) of the examined 5-HT6R antagonists were diluted to 200 µM in PBS
(phosphate-buffered saline, pH 7.4). Those solutions were added at 300 µL to the donor wells, whereas
wells on the receiver plate were filled with 200 µL of PBS. After 5 h of incubation at room temperature,
100 µL of solution were taken from each well and 100 µL of 200 µM of internal standard (IS) were
added. Samples prepared in this way were evaluated by the UPLC/MS Waters ACQUITYTM TQD
system with the TQ Detector (Waters, Milford, CT, USA) to estimate the concentrations from donor and
acceptor wells, as described previously [22]. The assay was performed in triplicate. The permeability
value (Pe) of examined compounds was calculated using the formula from the literature sources [21].
CFN and NFX were used as references.
3.2.3. Permeability Assay with Using Caco-2
The Caco-2 (ATCC® HTB-37TM) cell line was purchased from American Type Culture Collection
(ATCC) (Manassas, VG, USA). The cells were cultivated in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO2.
The medium was changed every two days, and the cells were subcultured at 70%–80% confluence.
The Corning® 3413 Transwell® 6.5 mm polycarbonate membrane inserts with 0.4 µm pores were
purchased from Sigma-Aldrich (Saint Louis, MO, USA). The inserts were pretreated first with 50 µL of
the medium for two minutes. Next, the 200 µL of cells were seeded at 2 × 10−4 concentration per insert
in apical compartment, whereas 600 µL was added to the basolateral one. The plate was incubated at
37 ◦C for 14 h, and the non-adherent cells were removed. TEER (transepithelial electrical resistance)
measurements was started from 18 days after seeding by Millicell ERS-2 Volt-Ohm Meter (Merck
Millipore, Burlington, MA, USA). The proper monolayer integrity was determined at 20 days after
seeding. Then, the monolayer was rinsed with HBSS (Hank’s balanced salt solution) and KMP-10, and
the highly permeable reference CFN was added at a 10 µM concentration with the HBSS into the apical
chambers. The 600 µL of HBSS was added to the basolateral compartments. Lucifer yellow (5 µM)
was also added to the apical chambers as the membrane integrity marker. The plate was placed in
the orbital shaker (60 rpm) for 2 h at 37 ◦C. The compounds’ concentrations in apical and basolateral
wells were analyzed using the UPLC-MS method with IS. To confirm the membrane integrity, the
fluorescence of lucifer yellow was measured in basolateral compartment by EnSpire multiplate reader
(Perkin Elmer, Waltham, MA, USA).
The apparent permeability Papp was calculated from two experiments according to the following
formula [34]:
Papp= dc/dt × V/(A × C0) (1)
where:
dc/dt—the change in concentration in the receiving compartment over time
V—volume of the solution in the receiving compartment (mL)
A—surface area of the membrane (cm2)
C0—the initial concentration in the donor compartment (µM).
3.2.4. Affinity to P-glycoprotein
The affinity to P-glycoprotein test was performed as described previously [22,35–37] by using
commercial the Pgp-GloTM Assay System (Promega, Madison, WI, USA), accordingly to the
manufacturer’s protocol. The reactions were prepared in triplicate in white polystyrene, flat-bottom
NuncTM MicroWellTM 96-well microplates (Thermo Scientific, Waltham, MA USA). The measurements
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of ATP consuming by Pgp was possible due to the light-generating reaction of firefly luciferase, and
these measurments were read by a microplate reader (EnSpire) in luminescence mode. The VL was
applied as the reference with a high stimulatory activity on Pgp. KMP-10 and DJ-18 were tested in
triplicates at 100 µM.
3.2.5. Plasma Protein Binding
The study was performed with use of the commercial TRANSILXL PPB Assay (Sovicell, Leipzig,
Germany). The test was performed according to recommendations from the protocol provided by the
manufacturer. Before the assay, the plate was thawed at room temperature for 3 h. The compounds
(stock solution in DMSO) were solved in a PBS buffer up to 320 µM. To each well of the 8-well tube units
(six wells containing different concentrations of human serum albumin (HSA) and α1-acid glycoprotein
(AGP) mixed in physiological ratio of 24:1 and two wells of references), 15 µL of the tested compound
solution was added to obtain 5 µM final concentration of WFN and KMP-10. The plate was incubated
on a plate shaker at 1000 rpm for 12 min. Next, the plate was centrifugated at 750 g for 10 min. The
supernatants were collected and analyzed by LC/MS. The PPB parameters of compound KMP-10 and
the highly bound reference WFN were calculated using the following equation:
KD =
[A] × [P]
[AP]
(2)
where:
A —free concentration of drug
P —free concentration of protein
AP —concentration of drug A bound to the protein P.
The total fraction bound was estimated by:
fb = 1−
1
1 + [HSA]
KHSAD
+
[AGP]
KAGPD
(3)
3.2.6. Metabolic Stability
The metabolic stability assays were performed as described in our previous articles [22,35–37].
The pharmacokinetic parameters of compounds were estimated by using human liver microsomes
(HLMs) (Sigma-Aldrich, St. Louis, MO, USA). The t1/2 values and intrinsic clearances (CLint) were
calculated with IS by using the protocols and formulas proposed by Obach [38]. The incubations were
terminated at 5, 15, 30 and 45 min. VL was used as the reference unstable drug.
The in vitro evaluation of metabolic pathways was performed by the prolonged, 120 min incubation
of compounds with HLMs. The in silico prediction of metabolic biotransformations was performed by
MetaSite 6.0.1 software (Molecular Discovery Ltd., Hertfordshire, UK) [39].
3.2.7. Drug–Drug Interaction (DDI)
The study was performed using the CYP3A4 P450-GloTM and CYP2D6 P450-GloTM commercial
tests provided by Promega (Madison, WI, USA). The influence of compounds on CYPs activity was
tested in white polystyrene, flat-bottom NuncTM MicroWellTM 96-well microplates (Thermo Scientific,
Waltham, MA USA), and the bioluminescence signal was measured with a microplate reader (EnSpire)
in luminescence mode, as described previously [22,35–37]. KMP-10 and DJ-18 were tested in triplicate
in the range of 0.01–25 µM for both isoforms’ P450 cytochrome. KE and QD were used as the reference
compounds for CYP3A4 and CYP2D6, respectively.
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3.2.8. Ames Test
The mutagenic activity was assessed by using the Ames MPF (Microplate Format Mutagenicity)
Assay [22,36–38] provided by Xenometrix AG (Allschwill, Switzerland), with the use of bacteria
Salmonella typhimurium strain TA100, thus enabling the detection of base-pair substitution. The growth
of reverted bacteria in 384-well plates was observed after 72 h of incubation at 37 ◦C throughout the
change of the color of the indicator medium from purple to yellow. The compounds were examined
in triplicate at concentrations 1 and 10 µM. The bacterial medium absorbance was measured with
a microplate reader (EnSpire) at the wavelength 420 nm. The mutagenicity was expressed in fold
increase above medium control baseline (MCB), where MCB ≥ 2 was considered as the mutagen alert.
NQNO was used as reference mutagen.
3.2.9. Hepatotoxicity Assay
Hepatotoxicity was estimated using the hepatoma HepG2 (ATCC® HB-8065TM) cell line according
to previously described protocols [22,35–37]. The CellTiter 96® AQueous Non-Radioactive Cell
Proliferation Assay was obtained from Promega (Madison, WI, USA). The compounds were investigated
in quadruplicate at four concentrations (0.1–100 µM) for 72h. The antiproliferative drug DX was used
as a positive control at a dose of 1 µM.
3.3. Behavioral Test In vivo
3.3.1. Animals
The experiments were performed on male Wistar rats (200–220 g) obtained from an accredited
animal facility at the Jagiellonian University Medical College, Poland. The animals were housed in
group of four in controlled environment (ambient temperature 21 ± 2 ◦C; relative humidity 50%–60%;
12-h light/dark cycles (lights on at 8:00). Standard laboratory food (LSM-B) and filtered water were
freely available. Animals were randomly assigned to treatment groups. All the experiments were
performed by two observers unaware of the studied treatment between 9:00 and 14:00 on separate
groups of animals. All animals were used only once. Procedures involving animals and their care
were conducted in accordance with current European Community and Polish legislation on animal
experimentation. Additionally, all efforts were made to minimize animal suffering and to use only
the number of animals necessary to produce reliable scientific data. The experimental protocols and
procedures described in this manuscript were approved by the I Local Ethics Commission in Cracow
(no 200/2018), complied with the European Communities Council Directive of 24 November 1986
(86/609/EEC), and were in accordance with the 1996 National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
3.3.2. Drugs
All compounds were suspended in 1% Tween 80 immediately before administration in a volume
of 2 mL/kg. Compounds were intraperitoneally administered 60 min before testing. Control animals
received vehicle (1% Tween 80) according to the same schedule.
3.3.3. Behavioral Procedures in Rats
Elevated Plus-Maze Test (EPM Test)
The testing procedure was based on a method described by [40]. The plus-maze apparatus
(an automated device produced by Campden Instruments Ltd. (United Kingdom) was made of
durable, high density, non-porous black plastic, elevated to a height of 50 cm, and consisted of two
open arms (50 × 10 cm) and two closed arms (50 × 10 cm, and 30 cm high walls) arranged so that the
two arms of each type were opposite each other. The floor of the plus-maze was made of infrared
transparent material, which means that there were no visible sensors. The plus-maze apparatus was
Molecules 2019, 24, 4472 19 of 24
connected to PC software by a control chassis. The experiments were conducted in a darkened room,
and only the center of the maze was illuminated with low-intensity light (30 lux measured on the
maze level). Each rat was gently placed in the center of the plus-maze, facing one of the closed arms,
immediately after a 5-min adaptation period in a plastic black box (60 × 60 × 35 cm), to increase the
overall activity in the EPM. During a 5-min test period, an automated motor monitor system recorded
the number of entries into the closed and open arms and the time spent in either type of arm. The
device counted an effective arm-entry when the four paws of a rat were into any arm. The maze was
thoroughly cleaned after each trial. The EPM test is an “unconditional” anxiety-like test based on
rodents’ natural aversion to heights and open space.
Exploratory Activity Measured in the EPM Test
The experiment was performed using an EPM apparatus (details see above). Total ambulation
(the total distance covered by a rat and ambulation along the X and Y axes) was taken into account to
discern drug effects on general activity from those on open-arm exploration during a 5-min test period
(i.e., the time equal to the observation period in the EPM test). Rats’ behavior was not videotaped
during the test.
Novel Object Recognition (NOR) Test
Five days before the experiment, the rats were transferred to the laboratory, labeled, and, thereafter,
left to acclimate to the new environment. The animals were handled every five days before experiments
to minimize the stress reaction. This protocol was adapted from the original work [41,42]. The test
session comprising two trials separated by an inter-trial interval (ITI) of 1 h was carried out on the
next day. During the first trial (familiarization, T1), two identical objects (A1 and A2) were presented
in the opposite corners of the open field, approximately 10 cm from the walls. During the second
trial (recognition, T2), one of the A objects was replaced by a novel object B so that the animals were
presented with the A = familiar and B = novel objects. Both trials lasted for 3 min, and the animals
were returned to their home cages after T1. The objects used were the metal Coca-Cola cans and the
glass jars filled with the sand. The heights of the objects were comparable (~12 cm), and the objects
were heavy enough to not be displaced by the animals. The sequence of presentations and the location
of the objects was randomly assigned to each rat. After each measurement, the floor was cleaned
and dried.
The animals explored the objects by looking, licking, sniffing or touching the object but not when
leaning against, standing or sitting on the object. Any rat exploring the two objects for less than 5 s
within 3 min of T1 or T2 was eliminated from the study. The exploration time of the objects was
measured by blind experimenter. Based on exploration time (E) of the two objects during T2, the
discrimination index (DI) was calculated according to the formula: DI = (EB − EA)/(EA + EB). Using
this metric, scores approaching zero reflected no preference, positive values reflected a preference for
the novel object, and negative numbers reflected a preference for the familiar.
Scopolamine and MK-801, used to attenuate learning, were administered at the dose of 0.1 mg/kg
(s.c. and i.p., respectively) 30 min before the familiarization phase (T1), while the investigated
compounds were given 60 min before T1 session.
3.3.4. Statistical Analysis
The data of behavioral studies were evaluated by an analysis of variance one-way ANOVA
followed by Bonferroni’s post-hoc test (statistical significance set at p < 0.05).
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3.4. Assays of Influence on Metabolism In vivo
3.4.1. Animals
The experiments were carried out on male Wistar rats. Their initial body weight was 210–230 g.
The animals were housed in pairs in plastic cages in constant temperature facilities exposed to a
light–dark cycle; water and food were available ad libitum. The control and experimental groups
consisted of eight animals each. All experiments were conducted according to the guidelines of the
Animal Use and Care Committee of the Jagiellonian University and were approved for realization
(2013 and 2015, Poland; Permissions No 136/2013 and 258/2015).
3.4.2. Drugs
Heparin was delivered by Polfa Warszawa S.A. (Warsaw, Poland), and thiopental sodium was
obtained from Sandoz GmbH, (Kundl, Austria).
3.4.3. The Effect of KMP-10 on Food and Water Intake by Non-Obese Rats Fed Palatable Diet (Model of
Excessive Eating)
In order to determine the anorectic activity of KMP-10, its effect on caloric and water intake
in the model of excessive eating was assessed [43,44]. Male Wistar rats were housed in pairs. Two
groups of 8 rats were fed diets consisting of milk chocolate with nuts, cheese, salted peanuts, and 7%
condensed milk; these rats also had access to a standard feed (Labofeed B, Morawski Manufacturer
Feed, Poland) and water ad libitum for 3 weeks. The palatable control group (palatable diet + vehicle)
received vehicle (1% Tween 80, i.p.), while the palatable test group (palatable diet + KMP-10 5 mg) was
intraperitoneally injected with KMP-10 at the dose 5 mg/kg b.w./day dissolved in 1% Tween 80. The
intakes of food and water were evaluated daily. On the 22th day, 20 min after the i.p. administration of
heparin 1000 units/rat and thiopental (70 mg/kg b.w.), blood, peritoneal fat pads, liver were collected
from animals.
The palatable diet contained 100 g of peanuts—614 kcal; 100 mL of condensed milk—131 kcal;
100 g of milk chocolate with hazelnuts—195 kcal; and 100 g of cheese (Greek type)—270 kcal.
The standard diet contained 100 g of feed—280 kcal.
The spontaneous activity of rats was measured on the 1st, 14th and 20th day of the treatment with
a special RFID-system—TraffiCage (TSE-Systems, Germany) [45,46]. The animals were subcutaneously
implanted with transmitter identification (RFID), which enabled the presence and time spent in
different areas of the cage to be counted; the data were then grouped in a special computer program.
3.4.4. The Effect of KMP-10 on Food and Water Intake by Non-Obese Rats Fed Only with Standard Diet
Male Wistar rats (190–220 g) were housed in pair. The control group (standard diet + vehicle)
received vehicle (1% Tween 80, i.p.), while the test group (standard diet + KMP-10 5 mg) was
intraperitoneally injected with KMP-10 at the dose 5 mg/kg b.w./day dissolved in 1% Tween 80. The
intakes of food and water were evaluated daily.
3.4.5. Influence of KMP-10 on Glucose, Cholesterol or Triglyceride Levels in Blood
To determine the glucose or cholesterol or triglyceride levels in blood, standard enzymatic and
spectrophotometric tests (Biomaxima S.A. Lublin, Poland) were used. The substrate was decomposed
with enzymes that were appropriate for the relevant product, which was converted to a colored
compound. Coloration was proportional to the concentration. The absorbance was measured at a
wavelength of 500 nm.
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3.4.6. Statistical Analysis
Statistical calculations were performed using the GraphPad Prism 6 program. Results are given
as arithmetic means with a standard error of the mean. Statistical significance was calculated using the
Student’s t-test (if two groups were compared) or a two-way ANOVA with Sidak’s multiple comparison
test post-hoc. Differences were considered statistically significant at: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
4. Conclusions
In response to the scientific and therapeutic challenge of medicinal chemistry to expand the
insufficient chemical space of active 5-HT6R ligands, this work has explored the most active members
of the original, non-indole and non-sulfone, triazine-hydantoin derivatives family. The comprehensive
studies performed, including docking, ADMET assays in vitro, and pharmacological tests in vivo
have shown beneficial properties of both the 2-naphthyl substituent or the general topology of
3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidaz
olidine-2,4-dione (KMP-10). These structural properties seem to be responsible for satisfying 5-HT6R
binding in a different mode from that of indole-containing (Idalopirdine) and sulfone-containing
(SUVN-502) antagonists. This mode can be crucial for a contribution in different response in
cellular level and is consequently promising for either potential new therapy or for the clarification
of the “agonist–antagonist paradox” observed for the ligands of 5-HT6R. A predominant role
of the naphthyl-containing 5-aryl-5-methyl-hydantoin topology (KMP-10) in comparison to the
5,5-dimethyl-1-arylmethyl-hydantoin one (DJ-18) can be seen not only in the receptor-binding aspect
but also in the “druglikeness” properties investigated in vitro. The obtained results indicated more
satisfying properties of KMP-10, with respect to DJ-18, in most of the ADMET assays performed.
In particular, better pharmacokinetics properties (CLint, t1/2) and lower risk of both DDI and toxic
effects of KMP-10 were confirmed. Finally, the 5-naphthylhydantoin derivative KMP-10 demonstrated
beneficial activities in the primary screening in vivo, including significant anxiolytic-like effects in both
“conditional” Vogel- and “unconditional” EPM assays, antidepressive-like properties in the Porsolt
model [19] and procognitive action, expressed as the potency to reverse scopolamine-induced memory
impairment in rats as well as favorable influence on body mass and metabolism in rats fed with the
palatable feed.
Taking the aforementioned data into account, the 5-naphthylhydantoin-1,3,5-triazine derivative
KMP-10 seems to be an interesting new lead-structure for either further pharmacological studies or
chemical modifications in order to find new therapeutic solutions via 5-HT6 receptor regulation.
Supplementary Materials: The following are available online, Figure S1: MS spectra of compound DJ-18 and its
main metabolite M1, Figure S2: MS/MS ion fragment analysis of compound DJ-18 and its main metabolite M1,
Figure S3: MS spectra of compound KMP-10 and its main metabolite M1, Figure S4: MS/MS ion fragment analysis
of compound DJ-18 and its main metabolite M1.
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